Double‐blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression

@article{Tanghe1997DoubleblindRC,
  title={Double‐blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression},
  author={A. Tanghe and S Geerts and J. Van Dorpe and B{\'e}n{\'e}dicte Brichard and Jacques Bruhwyler and Joseph G{\'e}czy},
  journal={Acta Psychiatrica Scandinavica},
  year={1997},
  volume={96}
}
The aim of this double‐blind randomized study was to compare the efficacy and the tolerability of moclobemide (300‐600 mg daily) and pirlindole (150‐300 mg daily), two reversible inhibitors of MAO‐A (RIMAs), in the treatment of depression. In total 116 patients were included in the trial, 111 patients (52 patients on pirlindole and 59 patients on moclobemide) were evaluable for efficacy and safety, and 77 patients completed the whole study (42 days of administration). Both treatments produced… 
Double‐Blind Randomized Controlled Pilot Study of the Efficacy and Tolerability of Pirlindole, a Reversible Inhibitor of Monoamine Oxidase A, and Mianserin, in the Treatment of Depression
This double‐blind randomized pilot study aimed to compare the efficacy and the tolerability of pirlindole (150–225 mg/day), a reversible inhibitor of monoamine oxidase A, and mianserin (60–90 mg/day)
Moclobemide: therapeutic use and clinical studies.
  • U. Bonnet
  • Psychology, Medicine
    CNS drug reviews
  • 2003
Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied in
Pirlindole in the Treatment of Depression
TLDR
A systematic review and meta-analysis of randomized controlled trials for the treatment of major depression in adults showed that all RCTs included reported efficacy outcomes for pirlindole comparable to those of its comparators, and that pirlindle was significantly better in terms of reducing anxiety symptoms.
Pirlindole in the Treatment of Depression and Fibromyalgia Syndrome
TLDR
The available evidence supports pirlindole as a safe and effective treatment option for the management of depression and fibromyalgia syndrome.
From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors
TLDR
The authors review the relevance of MAO isoforms to disease, and they also outline current research and development efforts in this class of drugs, including newer multipotent compounds.
Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome (Review)
TLDR
The effectiveness of MAOIs for the treatment of FM symptoms is limited and in people with FM:MAOIs may slightly improve pain and tender points in the short term compared to placebo, a Cochrane review shows.
Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome.
TLDR
Data suggest that the effectiveness of MAOIs for the treatment of FM symptoms is limited, and a moderate effect size on pain and a small one on tender points is observed.
Pirlindole and dehydropirlindole protect rat cultured neuronal cells against oxidative stress‐induced cell death through a mechanism unrelated to MAO‐A inhibition
TLDR
PIR and DHP can protect hippocampal and cortical neurons against oxidative stress at pharmacologically relevant concentrations and seems unrelated to inhibition of MAO‐A, but possibly involves free radical scavenging.
Emerging antidepressants to treat major depressive disorder.
Effective resolution of racemic pirlindole at the preparative scale
Pirlindole, a racemic antidepressant drug, was recently resolved using the derivatization method coupled with preparative HPLC. In order to improve this technique, the use of amino acid derivatives
...
...

References

SHOWING 1-10 OF 30 REFERENCES
Double‐Blind Randomized Controlled Pilot Study of the Efficacy and Tolerability of Pirlindole, a Reversible Inhibitor of Monoamine Oxidase A, and Mianserin, in the Treatment of Depression
This double‐blind randomized pilot study aimed to compare the efficacy and the tolerability of pirlindole (150–225 mg/day), a reversible inhibitor of monoamine oxidase A, and mianserin (60–90 mg/day)
A double‐blind randomized placebo‐controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression
TLDR
Pirlindole produced a significantly greater decrease than placebo in the Hamilton depression score, the Hamilton anxiety score, and the Montgomery‐Asberg depression score.
Pirlindole: Results of an Open Clinical Study in Out-Patients and of a Double-Blind Study Against Maprotiline
TLDR
A very good improvement of depressive symptomatology under medication in both treatment groups applies to both overall scores and to individual characteristics (symptoms).
Antidepressant efficacy and quality of life in depression: a double‐blind study with moclobemide and fluoxetine
TLDR
A significant change for the better in quality of life was found in both treatment groups, even at week 2 but especially after 6 weeks of treatment.
A double‐blind comparison of moclobemide and doxepin in depressed general practice patients
TLDR
Improvement was negatively correlated with age; this was statistically significant in the total group as well as in the MOC group, with a nonsignificant trend in the same direction in the DOX group.
A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.
TLDR
In the present double-blind study Moclobemide has been compared to placebo in a group of 34 unipolar psychotic or neurotic depressed patients and results have shown that the active drug was markedly superior to placebo.
A Double-blind Comparative Trial of Moclobemide v. Imipramine and Placebo in Major Depressive Episodes
TLDR
Patients suffering from a major depressive episode according to DSM-III criteria were randomly allocated to groups receiving either moclobemide, imipramine, or placebo treatment, and the overall assessment of tolerance clearly favoured placebo and moclOBemide over imipramsine.
Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase‐A, compared with other antidepressants and placebo
TLDR
It is concluded that moclobemide may be the second‐generation antidepressant doctors were waiting for, equally effective as the classical antidepressants but far better tolerated.
Moclobemide Versus Clomipramine in Endogenous Depression
TLDR
Tolerability was significantly better for moclobemide, as shown by the Clinical Global Impression of Tolerance (CGIT).
Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients
TLDR
Clinical studies show that, in elderly depressed patients, moclobemide is at least as effective as other antidepressants, and is as well tolerated in elderly people as in younger people.
...
...